Valuation : ImmunityBio, Inc.

Market Cap 8.38B 7.22B 6.84B 6.2B 11.63B 801B 11.69B 81.23B 31.24B 407B 31.48B 30.79B 1,288B P/E 2026 *
-8.24x
P/E 2027 * -55.5x
Enterprise Value 8.38B 7.22B 6.84B 6.2B 11.63B 801B 11.69B 81.23B 31.24B 407B 31.48B 30.79B 1,288B EV / Sales 2026 *
37.1x
EV / Sales 2027 * 19x
Free-Float
37.83%
Yield 2026 *
-
Yield 2027 * -
1 day+2.46%
1 week-2.10%
Current month-0.50%
1 month+2.20%
3 months+11.41%
6 months+1.15%
Current year+299.49%
1 week 7.64
Extreme 7.64
8.37
1 month 7.43
Extreme 7.4301
8.76
Current year 1.98
Extreme 1.98
12.43
1 year 1.95
Extreme 1.95
12.43
3 years 1.25
Extreme 1.25
12.43
5 years 1.21
Extreme 1.21
12.43
10 years 1.21
Extreme 1.21
40.83
Manager TitleAgeSince
Chief Executive Officer 57 2020-09-30
Chief Executive Officer 73 2015-02-28
Director of Finance/CFO 48 2021-02-28
Director TitleAgeSince
Director/Board Member 80 2021-01-31
Director/Board Member 71 2021-02-28
Chairman 73 2014-11-30
Date Insider Type Main position Quantity % Market Cap. Importance
7/2/26 Exercice

Director

243,168 0.0232%
7/1/26 Exercice

Director

478,434 0.0457%
6/30/26 Exercice

Director

3,000 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+2.46%-2.10%+204.23%+368.05% 8.38B
-2.11%-1.68%+43.40%+95.27% 66.93B
-0.23%-4.45%+32.50%+75.75% 61.97B
+1.67%+2.47%-11.32%+380.54% 28.26B
-1.05%-4.43%+28.84%+10.59% 24.59B
+0.34%-6.78%-0.01%-16.35% 24.3B
+0.43%-3.37%+16.22%-17.99% 19.41B
-3.03%-2.29%+181.72%+335.27% 16.77B
-1.94%-4.94%-8.15%+483.69% 14.18B
+3.24%-0.31%-7.34%+880.45% 14B
Average -0.02%-2.86%+48.01%+259.53% 27.88B
Weighted average by Cap. -0.47%-2.80%+36.46%+176.59%

Financials

2026 *2027 *
Net sales 226M 194M 184M 167M 313M 21.57B 315M 2.19B 841M 10.97B 848M 829M 34.67B 441M 380M 360M 326M 612M 42.18B 616M 4.28B 1.64B 21.46B 1.66B 1.62B 67.8B
Net income -1B -865M -819M -742M -1.39B -95.93B -1.4B -9.73B -3.74B -48.8B -3.77B -3.69B -154B -150M -129M -123M -111M -209M -14.36B -210M -1.46B -560M -7.31B -564M -552M -23.08B
Net Debt - -
Logo ImmunityBio, Inc.
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy.
Employees
688
Date Price Change Volume
26-09-11 US$7.910 +2.46% 12,468,768
26-09-10 US$7.720 -4.22% 8,805,734
26-09-09 US$8.060 -2.77% 9,488,937
26-09-08 US$8.290 +2.60% 7,741,308
26-09-04 US$8.080 -1.34% 4,330,218
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
7.910USD
Average target price
12.75USD
Spread / Average Target
+61.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IBRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!